Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Grace Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 17 | 20 | +3 |
| Shares | 4.02M | 3.82M | −207.2K (−5.1%) |
| Value | $9.17M | $11.3M | +$2.18M (+23.7%) |
New holders (4)
Institutions that held Grace Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millington Financial Advisors, LLC | 20,000 | $67.0K | 0.03% |
| Steward Partners Investment Advisory, LLC | 41 | $122 | 0.00% |
| Jones Financial Companies LLLP | 29 | $86 | 0.00% |
| Citigroup Inc | 1 | $3 | 0.00% |
Sold out (1)
Institutions that held Grace Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| JPMorgan Chase & Co | 15 | $34 |